News Alnylam Pharmaceuticals, Inc. Sao Paulo

Equities

A1LN34

BRA1LNBDR003

Delayed Sao Paulo Other stock markets 12:21:50 2024-06-28 EDT			5-day change	1st Jan Change
67.55 ^BRL	-.--%		+52.86%	+51.29%

06-28	UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating	MT
06-27	Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating	06-28	MT
Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating	06-27	MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $265 From $250, Keeps Outperform Rating	06-27	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $370,747, According to a Recent SEC Filing	06-26	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing	06-26	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $485,773, According to a Recent SEC Filing	06-26	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing	06-26	MT
Industry Leader John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor	06-26	AQ
Sector Update: Health Care Stocks Ease Late Afternoon	06-25	MT
Alnylam Pharmaceuticals Shares Rise as Heart Disease Candidate Meets Primary Endpoint in Late-Stage Study	06-25	MT
TD Cowen Adjusts Price Target on Alnylam Pharmaceuticals to $282 From $260, Maintains Buy Rating	06-25	MT
Barclays Raises Price Target on Alnylam Pharmaceuticals to $291 From $236, Maintains Overweight Rating	06-25	MT
Wells Fargo Raises Price Target on Alnylam Pharmaceuticals to $207 From $161, Maintains Equalweight Rating	06-25	MT
Out with AI, in with defensive stocks	06-25
Morgan Stanley Raises Alnylam Pharmaceuticals Price Target to $250 From $164, Maintains Equal Weight Rating	06-25	MT
Evercore ISI Boosts Price Target on Alnylam Pharmaceuticals to $260 From $210, Keeps Outperform Rating	06-25	MT
Chardan Raises Price Target on Alnylam Pharmaceuticals to $265 From $225, Keeps Buy Rating	06-25	MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $250 From $235, Keeps Outperform Rating	06-25	MT
ANALYST RECOMMENDATIONS : Capri Holdings, Adobe, Broadcom, Celanese, Admiral...	06-25
RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall, Monday, 6/24/2024	06-24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Alnylam Pharmaceuticals, Inc. Sao Paulo

Equities

A1LN34

BRA1LNBDR003

Summary

Filters